Gene PilotLX for Latinx Cancer Patients
This study is testing a new online tool called Gene PilotLX. This tool is designed to help Latinx cancer patients make informed decisions about genetic testing for hereditary cancer risks. Researchers want to see if Gene PilotLX helps patients understand their options better and communicate their preferences to their doctors. You might be able to join if you are 18 to 80 years old, identify as Latinx, have a solid tumor cancer, and can speak and read English or Spanish. The study will measure how well patients feel prepared to make decisions and how much conflict they have about those decisions. It will also look at how well patients communicate their preferences to their doctors. The study is currently recruiting 232 participants.
- Study design
- This is a randomized controlled trial with 232 planned participants. It is designed to evaluate the effectiveness of the Gene PilotLX tool.
- What's involved
- Not specified in the trial record.
- Compensation
- Not stated in the trial record.
- Follow-up
- Participants will have follow-up measurements at a post-test (which can be on the same day as baseline) and again at 1-3 months.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Testing Gene PilotLX With Latinx Cancer Patients
At a glance
Conditions
NCT06476938
Where you'd take part
This study runs at 4 sites. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.
Fox Chase Cancer Center
Philadelphia, Pennsylvaniano site contact published
Herbert Irving Comprehensive Cancer Center
New York, New Yorkno site contact published
MD Anderson Cancer Center at Cooper
Camden, New Jerseyno site contact published
Temple University Hospital
Philadelphia, Pennsylvaniano site contact published
Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.
Study leadership
- Michael J Hall, MD,MS · PRINCIPAL_INVESTIGATOR · Fox Chase Cancer Center
- Sarah B Bass, PhD, MPH · PRINCIPAL_INVESTIGATOR · Temple University
- Tracey A Revenson, PhD · PRINCIPAL_INVESTIGATOR · Hunter College of City University of New York
Who to contact
This trial hasn't published a contact. View it on ClinicalTrials.gov
What this trial measures
- Preparation for Decision Making (PrepDM) ScalePost-test (can occur on same day as baseline, day 1) and 1-3 month follow-up
PrepDM Scale measures preparedness of patient to make a decision (10 items) regarding a hereditary risk from tumor genomic profiling (TGP) on a 1 "not at all" to 5 "a great deal" scale. Higher means indicated higher perceived level of preparation for decision making.
- Decisional Conflict: Ottawa Decision Support Framework (ODSF) scalePost-test (can occur on same day as baseline, day 1) and 1-3 month follow-up
16- item measure to determine patient clarity on the risks and benefits of tumor genomic profiling (TGP) testing and hereditary risk information from TGP. Items are given a score value of: 0= 'strongly agree'; 2= 'neither agree nor disagree'; 3= 'disagree'; 4= 'strongly disagree' TOTAL SCORE 16 items are: a) summed; b) divided by 16; and c) multiplied by 25. Scores range from 0 \[no decisional conflict\] to 100 \[extremely high decisional conflict\]
- Communication of preferences to doctor related to pursuing hereditary cancer risk information from TGP1-3 month follow up
This is a single dichotomous item created for the study: 'Have you talked with a doctor about secondary hereditary results from TGP testing'?('Yes', 'No'). If 'Yes' is selected, 7 different topics for discussion with doctor are listed, including 'other' as open question.